Maribel Yazdanifar
Stanford University, Palo Alto, USA
Research Expertise
About
Publications
CAR‐NK cell in cancer immunotherapy; A promising frontier
Cancer Science / Jul 07, 2021
Marofi, F., Abdul‐Rasheed, O. F., Rahman, H. S., Budi, H. S., Jalil, A. T., Yumashev, A. V., Hassanzadeh, A., Yazdanifar, M., Motavalli, R., Chartrand, M. S., Ahmadi, M., Cid‐Arreguid, A., & Jarahian, M. (2021). CAR‐NK cell in cancer immunotherapy; A promising frontier. Cancer Science, 112(9), 3427–3436. Portico. https://doi.org/10.1111/cas.14993
CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth
Frontiers in Immunology / May 24, 2019
Zhou, R., Yazdanifar, M., Roy, L. D., Whilding, L. M., Gavrill, A., Maher, J., & Mukherjee, P. (2019). CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth. Frontiers in Immunology, 10. https://doi.org/10.3389/fimmu.2019.01149
γδ T Cells: The Ideal Tool for Cancer Immunotherapy
Cells / May 24, 2020
Yazdanifar, M., Barbarito, G., Bertaina, A., & Airoldi, I. (2020). γδ T Cells: The Ideal Tool for Cancer Immunotherapy. Cells, 9(5), 1305. https://doi.org/10.3390/cells9051305
A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies
Stem Cell Research & Therapy / Jul 28, 2021
Razeghian, E., Nasution, M. K. M., Rahman, H. S., Gardanova, Z. R., Abdelbasset, W. K., Aravindhan, S., Bokov, D. O., Suksatan, W., Nakhaei, P., Shariatzadeh, S., Marofi, F., Yazdanifar, M., Shamlou, S., Motavalli, R., & Khiavi, F. M. (2021). A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies. Stem Cell Research & Therapy, 12(1). https://doi.org/10.1186/s13287-021-02510-7
RETRACTED: CAR-NK Cell: A New Paradigm in Tumor Immunotherapy
Frontiers in Oncology / Jun 10, 2021
Marofi, F., Al-Awad, A. S., Sulaiman Rahman, H., Markov, A., Abdelbasset, W. K., Ivanovna Enina, Y., Mahmoodi, M., Hassanzadeh, A., Yazdanifar, M., Stanley Chartrand, M., & Jarahian, M. (2021). RETRACTED: CAR-NK Cell: A New Paradigm in Tumor Immunotherapy. Frontiers in Oncology, 11. https://doi.org/10.3389/fonc.2021.673276
A novel association of neuropilin-1 and MUC1 in pancreatic ductal adenocarcinoma: role in induction of VEGF signaling and angiogenesis
Oncogene / Jan 25, 2016
Zhou, R., Curry, J. M., Roy, L. D., Grover, P., Haider, J., Moore, L. J., Wu, S., Kamesh, A., Yazdanifar, M., Ahrens, W. A., Leung, T., & Mukherjee, P. (2016). A novel association of neuropilin-1 and MUC1 in pancreatic ductal adenocarcinoma: role in induction of VEGF signaling and angiogenesis. Oncogene, 35(43), 5608–5618. https://doi.org/10.1038/onc.2015.516
Overcoming Immunological Resistance Enhances the Efficacy of A Novel Anti-tMUC1-CAR T Cell Treatment against Pancreatic Ductal Adenocarcinoma
Cells / Sep 11, 2019
Yazdanifar, Zhou, Grover, Williams, Bose, Moore, Wu, Maher, Dreau, & Mukherjee. (2019). Overcoming Immunological Resistance Enhances the Efficacy of A Novel Anti-tMUC1-CAR T Cell Treatment against Pancreatic Ductal Adenocarcinoma. Cells, 8(9), 1070. https://doi.org/10.3390/cells8091070
CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies
Stem Cell Research & Therapy / Jul 02, 2021
Marofi, F., Saleh, M. M., Rahman, H. S., Suksatan, W., Al-Gazally, M. E., Abdelbasset, W. K., Thangavelu, L., Yumashev, A. V., Hassanzadeh, A., Yazdanifar, M., Motavalli, R., Pathak, Y., Naimi, A., Baradaran, B., Nikoo, M., & Khiavi, F. M. (2021). CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies. Stem Cell Research & Therapy, 12(1). https://doi.org/10.1186/s13287-021-02462-y
Evaluation of Cytokines in Multiple Sclerosis Patients Treated with Mesenchymal Stem Cells
Archives of Medical Research / May 01, 2013
Mohyeddin Bonab, M., Mohajeri, M., Sahraian, M. A., Yazdanifar, M., Aghsaie, A., Farazmand, A., & Nikbin, B. (2013). Evaluation of Cytokines in Multiple Sclerosis Patients Treated with Mesenchymal Stem Cells. Archives of Medical Research, 44(4), 266–272. https://doi.org/10.1016/j.arcmed.2013.03.007
Hurdles to breakthrough in CAR T cell therapy of solid tumors
Stem Cell Research & Therapy / Apr 01, 2022
Marofi, F., Achmad, H., Bokov, D., Abdelbasset, W. K., Alsadoon, Z., Chupradit, S., Suksatan, W., Shariatzadeh, S., Hasanpoor, Z., Yazdanifar, M., Shomali, N., & Khiavi, F. M. (2022). Hurdles to breakthrough in CAR T cell therapy of solid tumors. Stem Cell Research & Therapy, 13(1). https://doi.org/10.1186/s13287-022-02819-x
Treatment of pancreatic ductal adenocarcinoma with tumor antigen specific-targeted delivery of paclitaxel loaded PLGA nanoparticles
BMC Cancer / Apr 23, 2018
Wu, S., Fowler, A. J., Garmon, C. B., Fessler, A. B., Ogle, J. D., Grover, K. R., Allen, B. C., Williams, C. D., Zhou, R., Yazdanifar, M., Ogle, C. A., & Mukherjee, P. (2018). Treatment of pancreatic ductal adenocarcinoma with tumor antigen specific-targeted delivery of paclitaxel loaded PLGA nanoparticles. BMC Cancer, 18(1). https://doi.org/10.1186/s12885-018-4393-7
Antibody-Guided In Vivo Imaging for Early Detection of Mammary Gland Tumors
Translational Oncology / Aug 01, 2016
Moore, L. J., Roy, L. D., Zhou, R., Grover, P., Wu, S., Curry, J. M., Dillon, L. M., Puri, P. M., Yazdanifar, M., Puri, R., Mukherjee, P., & Dréau, D. (2016). Antibody-Guided In Vivo Imaging for Early Detection of Mammary Gland Tumors. Translational Oncology, 9(4), 295–305. https://doi.org/10.1016/j.tranon.2016.05.001
Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products
Pharmaceutical Research / Jun 01, 2021
Sadeqi Nezhad, M., Abdollahpour-Alitappeh, M., Rezaei, B., Yazdanifar, M., & Seifalian, A. M. (2021). Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products. Pharmaceutical Research, 38(6), 931–945. https://doi.org/10.1007/s11095-021-03067-z
Making a case for using γδ T cells against SARS-CoV-2
Critical Reviews in Microbiology / Oct 07, 2020
Yazdanifar, M., Mashkour, N., & Bertaina, A. (2020). Making a case for using γδ T cells against SARS-CoV-2. Critical Reviews in Microbiology, 46(6), 689–702. https://doi.org/10.1080/1040841x.2020.1822279
Abstract 2305: Tumor MUC1 glycoprotein-highly specific CAR T cells control triple-negative breast cancer
Immunology / Jul 01, 2019
Zhou, R., Yazdanifar, M., Roy, L. D., Maher, J., & Mukherjee, P. (2019, July 1). Abstract 2305: Tumor MUC1 glycoprotein-highly specific CAR T cells control triple-negative breast cancer. Immunology. https://doi.org/10.1158/1538-7445.sabcs18-2305
Strengthening the CAR‐T cell therapeutic application using CRISPR/Cas9 technology
Biotechnology and Bioengineering / Jul 21, 2021
Sadeqi Nezhad, M., Yazdanifar, M., Abdollahpour‐Alitappeh, M., Sattari, A., Seifalian, A., & Bagheri, N. (2021). Strengthening the CAR‐T cell therapeutic application using CRISPR/Cas9 technology. Biotechnology and Bioengineering, 118(10), 3691–3705. Portico. https://doi.org/10.1002/bit.27882
The Effect of Carrier Type on Bone Regeneration of Demineralized Bone Matrix In Vivo
Journal of Craniofacial Surgery / Nov 01, 2013
Tavakol, S., Khoshzaban, A., Azami, M., Kashani, I. R., Tavakol, H., Yazdanifar, M., & Sorkhabadi, S. M. R. (2013). The Effect of Carrier Type on Bone Regeneration of Demineralized Bone Matrix In Vivo. Journal of Craniofacial Surgery, 24(6), 2135–2140. https://doi.org/10.1097/scs.0b013e3182a243d4
Overexpression of MUC1 Induces Non-Canonical TGF-β Signaling in Pancreatic Ductal Adenocarcinoma
Frontiers in Cell and Developmental Biology / Feb 14, 2022
Bose, M., Grover, P., Sanders, A. J., Zhou, R., Ahmad, M., Shwartz, S., Lala, P., Nath, S., Yazdanifar, M., Brouwer, C., & Mukherjee, P. (2022). Overexpression of MUC1 Induces Non-Canonical TGF-β Signaling in Pancreatic Ductal Adenocarcinoma. Frontiers in Cell and Developmental Biology, 10. https://doi.org/10.3389/fcell.2022.821875
Harnessing Mechanisms of Immune Tolerance to Improve Outcomes in Solid Organ Transplantation: A Review
Frontiers in Immunology / Jun 10, 2021
Slepicka, P. F., Yazdanifar, M., & Bertaina, A. (2021). Harnessing Mechanisms of Immune Tolerance to Improve Outcomes in Solid Organ Transplantation: A Review. Frontiers in Immunology, 12. https://doi.org/10.3389/fimmu.2021.688460
Overcoming the UCB HSCs –Derived NK cells Dysfunction through Harnessing RAS/MAPK, IGF-1R and TGF-β Signaling Pathways
Cancer Cell International / Jun 07, 2021
Shokouhifar, A., Anani Sarab, G., Yazdanifar, M., Fereidouni, M., Nouri, M., & Ebrahimi, M. (2021). Overcoming the UCB HSCs –Derived NK cells Dysfunction through Harnessing RAS/MAPK, IGF-1R and TGF-β Signaling Pathways. Cancer Cell International, 21(1). https://doi.org/10.1186/s12935-021-01983-z
Delivery of miRNA-126 through folic acid-targeted biocompatible polymeric nanoparticles for effective lung cancer therapy
Journal of Bioactive and Compatible Polymers / May 01, 2022
Golafzani, F. N., Vaziri, A. Z., Javanmardi, M., Seyfan, F., Yazdanifar, M., & Khaleghi, S. (2022). Delivery of miRNA-126 through folic acid-targeted biocompatible polymeric nanoparticles for effective lung cancer therapy. Journal of Bioactive and Compatible Polymers, 37(3), 168–188. https://doi.org/10.1177/08839115221095152
Advances in therapeutic targeting of immune checkpoints receptors within the CD96-TIGIT axis: clinical implications and future perspectives
Expert Review of Clinical Immunology / Sep 26, 2022
Farhangnia, P., Akbarpour, M., Yazdanifar, M., Aref, A. R., Delbandi, A.-A., & Rezaei, N. (2022). Advances in therapeutic targeting of immune checkpoints receptors within the CD96-TIGIT axis: clinical implications and future perspectives. Expert Review of Clinical Immunology, 18(12), 1217–1237. https://doi.org/10.1080/1744666x.2022.2128107
Controversial role of γδ T cells in pancreatic cancer
International Immunopharmacology / Jul 01, 2022
Nezhad Shamohammadi, F., Yazdanifar, M., Oraei, M., Kazemi, M. H., Roohi, A., Mahya Shariat razavi, S., Rezaei, F., Parvizpour, F., Karamlou, Y., & Namdari, H. (2022). Controversial role of γδ T cells in pancreatic cancer. International Immunopharmacology, 108, 108895. https://doi.org/10.1016/j.intimp.2022.108895
Corrigendum: CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth
Frontiers in Immunology / Dec 07, 2020
Zhou, R., Yazdanifar, M., Roy, L. D., Whilding, L. M., Gavrill, A., Maher, J., & Mukherjee, P. (2020). Corrigendum: CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth. Frontiers in Immunology, 11. https://doi.org/10.3389/fimmu.2020.628776
Reconstructing the cell–cell interaction network among mouse immune cells
Biotechnology and Bioengineering / May 25, 2023
Azadian, S., Doustmohammadi, A., Naseri, M., Khodarahmi, M., Arab, S. S., Yazdanifar, M., Zahiri, J., & Lewis, N. E. (2023). Reconstructing the cell–cell interaction network among mouse immune cells. Biotechnology and Bioengineering, 120(9), 2756–2764. Portico. https://doi.org/10.1002/bit.28431
Abstract A37: Development and future of CAR T cell therapy for pancreatic ductal adenocarcinoma and triple negative breast cancer
Cancer Research / Nov 14, 2017
Mukherjee, P., Zhou, R., Yazdanifar, M., & Lopamudra, D. R. (2017). Abstract A37: Development and future of CAR T cell therapy for pancreatic ductal adenocarcinoma and triple negative breast cancer. Cancer Research, 77(22_Supplement), A37–A37. https://doi.org/10.1158/1538-7445.newfront17-a37
Mucin-1–Targeted Chimeric Antigen Receptor T Cells Are Effective and Safe in Controlling Solid Tumors in Immunocompetent Host
Journal of Immunotherapy / Jan 25, 2024
Zhou, R., Wu, S., Yazdanifar, M., Williams, C., Sanders, A., Brouwer, C., Maher, J., & Mukherjee, P. (2024). Mucin-1–Targeted Chimeric Antigen Receptor T Cells Are Effective and Safe in Controlling Solid Tumors in Immunocompetent Host. Journal of Immunotherapy, 47(3), 77–88. https://doi.org/10.1097/cji.0000000000000505
Protective and pathological roles of regulatory immune cells in human cytomegalovirus infection following hematopoietic stem cell transplantation
Reviews in Medical Virology / Dec 16, 2021
Namdari, H., Hosseini, M., Yazdanifar, M., Farajifard, H., Parvizpour, F., Karamigolbaghi, M., Hamidieh, A. A., & Rezaei, F. (2021). Protective and pathological roles of regulatory immune cells in human cytomegalovirus infection following hematopoietic stem cell transplantation. Reviews in Medical Virology, 32(4). Portico. https://doi.org/10.1002/rmv.2319
Tumor -Associated MUC1 Regulates TGF-β Signaling and Function in Pancreatic Ductal Adenocarcinoma
May 01, 2020
Grover, P., Nath, S., Bose, M., Sanders, A. J., Brouwer, C., Nitika, Zhou, R., Yazdanifar, M., Ahmad, M., Wu, S., Truman, A. W., & Mukherjee, P. (2020). Tumor -Associated MUC1 Regulates TGF-β Signaling and Function in Pancreatic Ductal Adenocarcinoma. https://doi.org/10.1101/2020.04.29.068577
Abstract 2636: Tumor associated MUC1 mediates TGF-β in pancreatic cancer
Cancer Research / Jul 01, 2019
Grover, P., Zhou, R., Yazdanifar, M., Ahmad, M., Puri, A., Grover, K., Shi, X., & Mukherjee, P. (2019). Abstract 2636: Tumor associated MUC1 mediates TGF-β in pancreatic cancer. Cancer Research, 79(13_Supplement), 2636–2636. https://doi.org/10.1158/1538-7445.am2019-2636
The use of tMUC1 highly specific chimeric antigen receptor-redirected T cells for the eradication of triple negative breast cancer
The Journal of Immunology / May 01, 2017
Zhou, R., Roy, L. D., Yazdanifar, M., Livasy, C., & Mukherjee, P. (2017). The use of tMUC1 highly specific chimeric antigen receptor-redirected T cells for the eradication of triple negative breast cancer. The Journal of Immunology, 198(1_Supplement), 198.10-198.10. https://doi.org/10.4049/jimmunol.198.supp.198.10
Retraction: CAR-NK Cell: a new paradigm in tumor immunotherapy
Frontiers in Oncology / Sep 04, 2023
(2023). Retraction: CAR-NK Cell: a new paradigm in tumor immunotherapy. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1285219
Retraction: Mesenchymal stem/stromal cell-based delivery: a rapidly evolving strategy for cancer therapy
Frontiers in Cell and Developmental Biology / Sep 04, 2023
(2023). Retraction: Mesenchymal stem/stromal cell-based delivery: a rapidly evolving strategy for cancer therapy. Frontiers in Cell and Developmental Biology, 11. https://doi.org/10.3389/fcell.2023.1285267
Abstract 2305: Tumor MUC1 glycoprotein-highly specific CAR T cells control triple-negative breast cancer
Cancer Research / Jul 01, 2019
Zhou, R., Yazdanifar, M., Roy, L. D., Maher, J., & Mukherjee, P. (2019). Abstract 2305: Tumor MUC1 glycoprotein-highly specific CAR T cells control triple-negative breast cancer. Cancer Research, 79(13_Supplement), 2305–2305. https://doi.org/10.1158/1538-7445.am2019-2305
Abstract 584: Developing a novel engineered T cell to target resistant pancreatic cancer
Cancer Research / Jul 01, 2019
Yazdanifar, M., Zhou, R., Wu, S., Grover, P., & Mukherjee, P. (2019). Abstract 584: Developing a novel engineered T cell to target resistant pancreatic cancer. Cancer Research, 79(13_Supplement), 584–584. https://doi.org/10.1158/1538-7445.am2019-584
Front Matter
Basics of Chimeric Antigen Receptor (CAR) Immunotherapy / Jan 01, 2019
Front Matter. (2019). In Basics of Chimeric Antigen Receptor (CAR) Immunotherapy (p. iii). Elsevier. https://doi.org/10.1016/b978-0-12-819573-4.01001-2
Abstract 3464: MUC1 regulates TGF-β in pancreatic cancer
Cancer Research / Jul 01, 2018
Grover, P., Yazdanifar, M., Ahmad, M., Zhou, R., Puri, A., Grover, K., Shi, X., & Mukherjee, P. (2018). Abstract 3464: MUC1 regulates TGF-β in pancreatic cancer. Cancer Research, 78(13_Supplement), 3464–3464. https://doi.org/10.1158/1538-7445.am2018-3464
Abstract 4708: A novel anti-MUC1 CAR T cell drives immunity to pancreatic cancer
Cancer Research / Jul 01, 2017
Yazdanifar, M., Zhou, R., Wu, S., Grover, P., & Mukherjee, P. (2017). Abstract 4708: A novel anti-MUC1 CAR T cell drives immunity to pancreatic cancer. Cancer Research, 77(13_Supplement), 4708–4708. https://doi.org/10.1158/1538-7445.am2017-4708
Abstract 321: MUC1 regulates TGFβ function in pancreatic cancer
Cancer Research / Jul 01, 2017
Grover, P., Nye, M. D., Yazdanifar, M., Ahmad, M., Zhou, R., Roy, L. D., Grover, K., Wu, S., Nath, S., & Mukherjee, P. (2017). Abstract 321: MUC1 regulates TGFβ function in pancreatic cancer. Cancer Research, 77(13_Supplement), 321–321. https://doi.org/10.1158/1538-7445.am2017-321
Engineering the Bridge between Innate and Adaptive Immunity for Cancer Immunotherapy: Focus on γδ T and NK Cells
Cells / Jul 22, 2020
Morandi, F., Yazdanifar, M., Cocco, C., Bertaina, A., & Airoldi, I. (2020). Engineering the Bridge between Innate and Adaptive Immunity for Cancer Immunotherapy: Focus on γδ T and NK Cells. Cells, 9(8), 1757. https://doi.org/10.3390/cells9081757
RETRACTED: A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions
Frontiers in Immunology / Jun 23, 2021
Marofi, F., Rahman, H. S., Achmad, M. H., Sergeevna, K. N., Suksatan, W., Abdelbasset, W. K., Mikhailova, M. V., Shomali, N., Yazdanifar, M., Hassanzadeh, A., Ahmadi, M., Motavalli, R., Pathak, Y., Izadi, S., & Jarahian, M. (2021). RETRACTED: A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions. Frontiers in Immunology, 12. https://doi.org/10.3389/fimmu.2021.681984
RETRACTED: Harnessing TRAIL-Induced Apoptosis Pathway for Cancer Immunotherapy and Associated Challenges
Frontiers in Immunology / Aug 20, 2021
Razeghian, E., Suksatan, W., Sulaiman Rahman, H., Bokov, D. O., Abdelbasset, W. K., Hassanzadeh, A., Marofi, F., Yazdanifar, M., & Jarahian, M. (2021). RETRACTED: Harnessing TRAIL-Induced Apoptosis Pathway for Cancer Immunotherapy and Associated Challenges. Frontiers in Immunology, 12. https://doi.org/10.3389/fimmu.2021.699746
RETRACTED: Mesenchymal Stem/Stromal Cells as a Vehicle for Cytokine Delivery: An Emerging Approach for Tumor Immunotherapy
Frontiers in Medicine / Aug 27, 2021
Razeghian, E., Margiana, R., Chupradit, S., Bokov, D. O., Abdelbasset, W. K., Marofi, F., Shariatzadeh, S., Tosan, F., & Jarahian, M. (2021). RETRACTED: Mesenchymal Stem/Stromal Cells as a Vehicle for Cytokine Delivery: An Emerging Approach for Tumor Immunotherapy. Frontiers in Medicine, 8. https://doi.org/10.3389/fmed.2021.721174
RETRACTED: Mesenchymal Stem/Stromal Cell-Based Delivery: A Rapidly Evolving Strategy for Cancer Therapy
Frontiers in Cell and Developmental Biology / Jul 12, 2021
Hassanzadeh, A., Altajer, A. H., Rahman, H. S., Saleh, M. M., Bokov, D. O., Abdelbasset, W. K., Marofi, F., Zamani, M., Yaghoubi, Y., Yazdanifar, M., Pathak, Y., Chartrand, M. S., & Jarahian, M. (2021). RETRACTED: Mesenchymal Stem/Stromal Cell-Based Delivery: A Rapidly Evolving Strategy for Cancer Therapy. Frontiers in Cell and Developmental Biology, 9. https://doi.org/10.3389/fcell.2021.686453
Education
University of North Carolina at Charlotte
PhD/Dr, Biological Sciences / August, 2019
Experience
Stanford medicine
Postdoctoral scholar / November, 2019 — Present
Join Maribel on NotedSource!
Join Now
At NotedSource, we believe that professors, post-docs, scientists and other researchers have deep, untapped knowledge and expertise that can be leveraged to drive innovation within companies. NotedSource is committed to bridging the gap between academia and industry by providing a platform for collaboration with industry and networking with other researchers.
For industry, NotedSource identifies the right academic experts in 24 hours to help organizations build and grow. With a platform of thousands of knowledgeable PhDs, scientists, and industry experts, NotedSource makes connecting and collaborating easy.
For academic researchers such as professors, post-docs, and Ph.D.s, NotedSource provides tools to discover and connect to your colleagues with messaging and news feeds, in addition to the opportunity to be paid for your collaboration with vetted partners.
Expert Institutions
Proudly trusted by
